** Divi's Laboratories DIVI.NS up 1.6% at ~3,680 rupees,
among top Nifty 50 .NSEI gainers
** BofA Securities double upgrades the drug ingredients
maker's stock to "buy" from "underperform" on improving earnings
outlook and attractive valuation; raises PT to 4,025 rupees
** Brokerage says Divi's is more compelling due to lower
risk to earnings growth than at US-focused generic drug makers,
who are susceptible to pricing uncertainties
** Expects Divi's EBITDA margins to rise to 33% by FY26 (vs
35% pre-COVID), after likely bottoming out at 27% in FY24
** Despite the upgrade, analysts' avg rating on Divi's
remains "sell", per LSEG data
** Wipro WIPR.NS is the only other Nifty 50 stock with an
avg "sell" rating
** DIVI trims YTD losses to ~6%; is among three stocks on
20-member Nifty pharma .NIPHARM in the red this year
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))